Vector-mediated Gene Transfer Engenders Long-lived Neutralizing Activity and Protection Against SIV Infection in Monkeys

Overview

Journal Nat Med

Specialties General Medicine
Molecular Biology

Date 2009 May 19

PMID 19448633

Citations 190

Authors

Philip R Johnson

Bruce C Schnepp

Jianchao Zhang

Mary J Connell

Sean M Greene

Eloisa Yuste

Ronald C Desrosiers

K Reed Clark

Affiliations

Soon will be listed here.

Abstract

The key to an effective HIV vaccine is development of an immunogen that elicits persisting antibodies with broad neutralizing activity against field strains of the virus. Unfortunately, very little progress has been made in finding or designing such immunogens. Using the simian immunodeficiency virus (SIV) model, we have taken a markedly different approach: delivery to muscle of an adeno-associated virus gene transfer vector expressing antibodies or antibody-like immunoadhesins having predetermined SIV specificity. With this approach, SIV-specific molecules are endogenously synthesized in myofibers and passively distributed to the circulatory system. Using such an approach in monkeys, we have now generated long-lasting neutralizing activity in serum and have observed complete protection against intravenous challenge with virulent SIV. In essence, this strategy bypasses the adaptive immune system and holds considerable promise as a unique approach to an effective HIV vaccine.

Citing Articles

Effective Reduction of Transgene-Specific Immune Response With rAAV Vectors Co-Expressing miRNA-UL112-5p or ERAP1 shRNA.

Huang X, Wang X, Sun Y, Xie X, Xiao L, Xu Y J Cell Mol Med. 2025; 29(2):e70308.

PMID: 39823241 PMC: 11740984. DOI: 10.1111/jcmm.70308.

Enhancing broadly neutralising antibody suppression of HIV by immune modulation and vaccination.

Nel C, Frater J Front Immunol. 2024; 15:1478703.

PMID: 39575236 PMC: 11578998. DOI: 10.3389/fimmu.2024.1478703.

HIV Persistence, Latency, and Cure Approaches: Where Are We Now?.

Chou T, Maggirwar N, Marsden M Viruses. 2024; 16(7).

PMID: 39066325 PMC: 11281696. DOI: 10.3390/v16071163.

HIV broadly neutralizing antibody escapability drives the therapeutic efficacy of vectored immunotherapy.

Galvez N, Cao Y, Nitido A, Deal C, Boutros C, MacDonald S bioRxiv. 2024; .

PMID: 39026699 PMC: 11257540. DOI: 10.1101/2024.07.11.603156.

Adeno-associated viral delivery of Env-specific antibodies prevents SIV rebound after discontinuing antiretroviral therapy.

Klenchin V, Clark N, Keles N, Capuano S, Mason R, Gao G bioRxiv. 2024; .

PMID: 38895320 PMC: 11185534. DOI: 10.1101/2024.05.30.593694.

References

Mori K, Ringler D, Kodama T, Desrosiers R . Complex determinants of macrophage tropism in env of simian immunodeficiency virus. J Virol. 1992; 66(4):2067-75. PMC: 288997. DOI: 10.1128/JVI.66.4.2067-2075.1992. View

Baba T, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S . Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med. 2000; 6(2):200-6. DOI: 10.1038/72309. View

Lewis A, Chen R, Montefiori D, Johnson P, Clark K . Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer. J Virol. 2002; 76(17):8769-75. PMC: 136414. DOI: 10.1128/jvi.76.17.8769-8775.2002. View

Hessell A, Hangartner L, Hunter M, Havenith C, Beurskens F, Bakker J . Fc receptor but not complement binding is important in antibody protection against HIV. Nature. 2007; 449(7158):101-4. DOI: 10.1038/nature06106. View

Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F . Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis. 2006; 194(12):1661-71. DOI: 10.1086/508748. View

Yuvaraj S, Al-Lahham S, Lahham S, Marreddy R, Dijkstra G, Wolken W . Human scFv SIgA expressed on Lactococcus lactis as a vector for the treatment of mucosal disease. Mol Nutr Food Res. 2008; 52(8):913-20. DOI: 10.1002/mnfr.200700132. View

Binley J, Lybarger E, Crooks E, Seaman M, Gray E, Davis K . Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol. 2008; 82(23):11651-68. PMC: 2583680. DOI: 10.1128/JVI.01762-08. View

Davidoff A, Gray J, Ng C, Zhang Y, Zhou J, Spence Y . Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. Mol Ther. 2005; 11(6):875-88. DOI: 10.1016/j.ymthe.2004.12.022. View

Johnson W, Sanford H, Schwall L, Burton D, Parren P, Robinson J . Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities. J Virol. 2003; 77(18):9993-10003. PMC: 224602. DOI: 10.1128/jvi.77.18.9993-10003.2003. View

10.

Schnepp B, Jensen R, Clark K, Johnson P . Infectious molecular clones of adeno-associated virus isolated directly from human tissues. J Virol. 2008; 83(3):1456-64. PMC: 2620885. DOI: 10.1128/JVI.01686-08. View

11.

Frade R, Rousselet N, Jean D . Intratumoral gene delivery of anti-cathepsin L single-chain variable fragment by lentiviral vector inhibits tumor progression induced by human melanoma cells. Cancer Gene Ther. 2008; 15(9):591-604. DOI: 10.1038/cgt.2008.51. View

12.

Burton D, Pyati J, Koduri R, Sharp S, Thornton G, Parren P . Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science. 1994; 266(5187):1024-7. DOI: 10.1126/science.7973652. View

13.

Fang J, Yi S, Simmons A, Tu G, Nguyen M, Harding T . An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies in vivo. Mol Ther. 2007; 15(6):1153-9. DOI: 10.1038/sj.mt.6300142. View

14.

Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N . Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol. 1996; 70(2):1100-8. PMC: 189917. DOI: 10.1128/JVI.70.2.1100-1108.1996. View

15.

Cadogan M, Dalgleish A . HIV immunopathogenesis and strategies for intervention. Lancet Infect Dis. 2008; 8(11):675-84. DOI: 10.1016/S1473-3099(08)70205-6. View

16.

Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G . A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol. 1993; 67(11):6642-7. PMC: 238102. DOI: 10.1128/JVI.67.11.6642-6647.1993. View

17.

Kasuya K, Boyer J, Tan Y, Alipui D, Hackett N, Crystal R . Passive immunotherapy for anthrax toxin mediated by an adenovirus expressing an anti-protective antigen single-chain antibody. Mol Ther. 2005; 11(2):237-44. DOI: 10.1016/j.ymthe.2004.10.018. View

18.

Barash S, Wang W, Shi Y . Human secretory signal peptide description by hidden Markov model and generation of a strong artificial signal peptide for secreted protein expression. Biochem Biophys Res Commun. 2002; 294(4):835-42. DOI: 10.1016/S0006-291X(02)00566-1. View

19.

Herzog R, Yang E, Couto L, Hagstrom J, Elwell D, Fields P . Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med. 1999; 5(1):56-63. DOI: 10.1038/4743. View

20.

McCarty D, Fu H, Monahan P, Toulson C, Naik P, Samulski R . Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther. 2003; 10(26):2112-8. DOI: 10.1038/sj.gt.3302134. View